Egetis Therapeutics AB (publ) announced that the first patient has been included and a second site has been activated in the pivotal ReTRIACt clinical trial for the new drug application (NDA) in the USA for The trial will be conducted across three centers: at Erasmus Medical Center, Rotterdam, the Emcitate. Netherlands, Children's Hospital of Philadelphia, Philadelphia, PA, USA, and Addenbrooke's Hospital, Cambridge, UK. As previously reported, the Company expects topline results from the ReTRIACt study during the first half of 2024 and estimates a subsequent NDA submission in the USA in mid-2024, under the fast-track designation.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.49 SEK | +5.20% | +22.19% | +34.23% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.23% | 195M | |
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.64% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- EGTX Stock
- News Egetis Therapeutics AB
- Egetis Therapeutics AB Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial